Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort

J. Mazieres, G. Zalcman, L. Crino, P. Biondani, F. Barlesi, T. Filleron, A.M.C. Dingemans, H. Lena, I. Monnet, S.I. Rothschild, F. Cappuzzo, B. Besse, L. Thiberville, D. Rouviere, R Dziadziuszko, E.F. Smit, J. Wolf, C. Spirig, N. Pecuchet, F. LeendersJ.M. Heuckmann, J. Diebold, J.D. Milia, R.K. Thomas, O. Gautschi

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)992-999
JournalJournal of Clinical Oncology
Volume33
Issue number9
DOIs
Publication statusPublished - 2015

Cite this

Mazieres, J., Zalcman, G., Crino, L., Biondani, P., Barlesi, F., Filleron, T., ... Gautschi, O. (2015). Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort. Journal of Clinical Oncology, 33(9), 992-999. https://doi.org/10.1200/JCO.2014.58.3302